vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and High Roller Technologies, Inc. (ROLR). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $6.3M, roughly 2.0× High Roller Technologies, Inc.). High Roller Technologies, Inc. runs the higher net margin — 58.4% vs -1398.3%, a 1456.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -16.4%). High Roller Technologies, Inc. produced more free cash flow last quarter ($-90.0K vs $-156.9M).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

S&S – Sansei Technologies is an American company known for its pneumatically powered amusement rides and roller coaster designing.

RNA vs ROLR — Head-to-Head

Bigger by revenue
RNA
RNA
2.0× larger
RNA
$12.5M
$6.3M
ROLR
Growing faster (revenue YoY)
RNA
RNA
+450.5% gap
RNA
434.0%
-16.4%
ROLR
Higher net margin
ROLR
ROLR
1456.7% more per $
ROLR
58.4%
-1398.3%
RNA
More free cash flow
ROLR
ROLR
$156.8M more FCF
ROLR
$-90.0K
$-156.9M
RNA

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
RNA
RNA
ROLR
ROLR
Revenue
$12.5M
$6.3M
Net Profit
$-174.4M
$3.7M
Gross Margin
Operating Margin
-1513.5%
1.3%
Net Margin
-1398.3%
58.4%
Revenue YoY
434.0%
-16.4%
Net Profit YoY
-117.0%
831.9%
EPS (diluted)
$-1.27
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
ROLR
ROLR
Q3 25
$12.5M
$6.3M
Q2 25
$3.8M
$6.9M
Q1 25
$1.6M
$6.8M
Q4 24
$3.0M
Q3 24
$2.3M
$7.5M
Q2 24
$2.0M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
RNA
RNA
ROLR
ROLR
Q3 25
$-174.4M
$3.7M
Q2 25
$-157.3M
$-592.0K
Q1 25
$-115.8M
$-3.3M
Q4 24
$-102.3M
Q3 24
$-80.4M
$-501.0K
Q2 24
$-70.8M
Q1 24
$-68.9M
Q4 23
$-60.4M
Operating Margin
RNA
RNA
ROLR
ROLR
Q3 25
-1513.5%
1.3%
Q2 25
-4448.7%
-7.2%
Q1 25
-8360.9%
-47.4%
Q4 24
-4069.6%
Q3 24
-4200.9%
-6.3%
Q2 24
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
RNA
RNA
ROLR
ROLR
Q3 25
-1398.3%
58.4%
Q2 25
-4089.3%
-8.5%
Q1 25
-7360.0%
-48.4%
Q4 24
-3439.5%
Q3 24
-3441.7%
-6.7%
Q2 24
-3461.8%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
RNA
RNA
ROLR
ROLR
Q3 25
$-1.27
$0.39
Q2 25
$-1.21
$-0.07
Q1 25
$-0.90
$-0.39
Q4 24
$-0.80
Q3 24
$-0.65
$-0.07
Q2 24
$-0.65
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
ROLR
ROLR
Cash + ST InvestmentsLiquidity on hand
$350.2M
$2.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$6.6M
Total Assets
$2.1B
$16.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
ROLR
ROLR
Q3 25
$350.2M
$2.7M
Q2 25
$243.9M
$2.7M
Q1 25
$254.2M
$3.5M
Q4 24
$219.9M
Q3 24
$370.2M
$1.3M
Q2 24
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Stockholders' Equity
RNA
RNA
ROLR
ROLR
Q3 25
$1.9B
$6.6M
Q2 25
$1.2B
$2.6M
Q1 25
$1.3B
$2.8M
Q4 24
$1.4B
Q3 24
$1.5B
$-779.0K
Q2 24
$1.2B
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
RNA
RNA
ROLR
ROLR
Q3 25
$2.1B
$16.0M
Q2 25
$1.4B
$12.3M
Q1 25
$1.5B
$12.8M
Q4 24
$1.6B
Q3 24
$1.6B
$12.9M
Q2 24
$1.3B
Q1 24
$951.5M
Q4 23
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
ROLR
ROLR
Operating Cash FlowLast quarter
$-156.2M
$-78.0K
Free Cash FlowOCF − Capex
$-156.9M
$-90.0K
FCF MarginFCF / Revenue
-1257.6%
-1.4%
Capex IntensityCapex / Revenue
5.7%
0.2%
Cash ConversionOCF / Net Profit
-0.02×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
ROLR
ROLR
Q3 25
$-156.2M
$-78.0K
Q2 25
$-199.7M
$-840.0K
Q1 25
$-124.8M
$-3.6M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
RNA
RNA
ROLR
ROLR
Q3 25
$-156.9M
$-90.0K
Q2 25
$-203.0M
$-845.0K
Q1 25
$-128.6M
$-3.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
RNA
RNA
ROLR
ROLR
Q3 25
-1257.6%
-1.4%
Q2 25
-5277.1%
-12.2%
Q1 25
-8174.3%
-53.5%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
RNA
RNA
ROLR
ROLR
Q3 25
5.7%
0.2%
Q2 25
86.9%
0.1%
Q1 25
238.6%
0.2%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%
Cash Conversion
RNA
RNA
ROLR
ROLR
Q3 25
-0.02×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RNA
RNA

Segment breakdown not available.

ROLR
ROLR

Net Gaming Revenue$4.9M77%
Net Revenue Noncore Services$1.4M23%

Related Comparisons